GT919, a molecular glue, directly binds to the substrate receptor Cereblon (CRBN) in CRL4CRBN E3 ubiquitin ligase complex, and then recruits substrate proteins such as the transcription factors IKZF1 and IKZF3 to induce their ubiquitination and further degradation of the substrate proteins, driving to display anti-tumor effects and immune regulations. GT919 is a new generation of immunomodulatory drug in clinical trial, aming to overcome resistance of existing drugs such as Lenalidomide and Pomalidomide.

GT929 directly binds to the substrate receptor Cereblon (CRBN) of the CRL4CRBN E3 ubiquitin ligase complex, and then recruits and induce the ubiquitination and further degradation of pathogenic proteins IKZF1 and IKZF3 in NHL, driving to play the roles of anti-tumor effects and immune regulations.

GT818 is a first-in-class GLUETAC degrader, showing significant anti-tumor effects in a variety of CDX models across solid tumors and liquid tumors, such as TNBC, AR-prostate cancer, SCLC, colorectal cancer and ATCL, aiming to meet unmet medical needs in these tumors.

GT820 is a first-in-class GLUETAC degrader, showing identification and significant proliferation inhibition of hepatocellular carcinoma cell lines with high specificity. GT820, downregulating RAS signaling and inhibiting angiogenesis pathway, has great tumor growth inhibition in hepatocellular carcinoma CDX models.